---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-032227"
form_type: "8-K"
ticker: "CSBR"
cik: "0000771856"
company_name: "CHAMPIONS ONCOLOGY, INC."
filed_at: "2024-07-18T23:59:59+00:00"
generated_at: "2026-05-31T19:59:35.404500+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Champions Oncology reports FY2024 revenue down 7% to $50.2M; Q4 adjusted EBITDA turns positive $884K

## Summary
- Q4 revenue $14.0M (+7% YoY); Q4 adjusted EBITDA income $884K vs loss $922K prior year.
- FY2024 revenue $50.2M (-7% YoY); FY adjusted EBITDA loss $3.9M vs loss $1.3M prior year.
- Q4 gross margin 48% (pharmacology services 49%); FY gross margin 41% vs 45% prior year.
- Cash $2.6M, no debt; stock repurchase program paused; Corellia AI unit seeking external capital.
- Q4 operating loss $190K narrowed from $2.5M prior year; cost-cutting measures improving bottom line.

## SEC filing metadata
- accession: 0001628280-24-032227
- form_type: 8-K
- ticker: CSBR
- cik: 0000771856
- company_name: CHAMPIONS ONCOLOGY, INC.
- filed_at: 2024-07-18T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/771856/000162828024032227/0001628280-24-032227-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/771856/000162828024032227/csbr-20240718.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-032227
- JSON: https://secwatch.observer/filing/0001628280-24-032227.json
- Plain text: https://secwatch.observer/filing/0001628280-24-032227.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.